Anna Kress, MD
Assistant Professor of Medicine (Hematology)DownloadHi-Res Photo
Cards
Appointments
Hematology
Primary
Contact Info
About
Titles
Assistant Professor of Medicine (Hematology)
Biography
Dr. Kress received her medical degree from Columbia University Vagelos College of Physicians and Surgeons. Her internship and residency were completed at Columbia University Medical Center, NY Presbyterian Hospital. After residency, Dr. Kress completed her fellowship in Medical Oncology and Hematology at Yale New Haven Hospital and served as chief fellow in her third year. Dr. Kress’s clinical and research interests include B-cell lymphomas and non-malignant hematologic diseases.
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Internal Medicine Resident
- Columbia University, New York Presbyterian Hospital (2019)
- MD
- Columbia University, College of P&S (2016)
- BA
- Cornell University (2010)
Research
Overview
Dr. Kress’s clinical and research interests include B-cell lymphomas and non-malignant hematologic diseases.
Medical Subject Headings (MeSH)
Hematologic Diseases
Research at a Glance
Yale Co-Authors
Frequent collaborators of Anna Kress's published research.
Shalin Kothari, MD
Nataliya Sostin, MD, MCR
Chad Binns, MD
Publications
2023
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProgression-free survivalMulti-institutional retrospective studyHigh-grade B-cell lymphomaOverall survivalB-cell lymphomaComplete responseMYC rearrangementRetrospective studyBCL6 rearrangementsGerminal center B-cell immunophenotypeHigh serum lactate dehydrogenaseHigh-risk clinical factorsBetter progression-free survivalIntensive chemotherapy programsPoor performance statusStage IV diseaseFirst-line regimensMain prognostic factorsDose-intense chemotherapyHigh-grade morphologic featuresSerum lactate dehydrogenaseB-cell immunophenotypeDA-EPOCHR-CHOPMost patientsWarm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity
Jacobs J, Binns T, Abels E, Campos J, Elkabbani R, Kress A, Sostin N, Tormey C. Warm autoantibodies mimicking alloantibodies: Three cases of autoantibodies with unusual antigenic specificity. American Journal Of Clinical Pathology 2023, 160: 561-565. PMID: 37598315, DOI: 10.1093/ajcp/aqad095.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsWarm autoantibodiesRed blood cellsAntigenic specificityCase of autoantibodiesCase 1Autoimmune hemolytic anemiaDirect antiglobulin testRBC transfusionPregnant womenTransfusion reactionsAntiglobulin testHemolytic anemiaAutoantibodiesRBC antigensAntibody detectionRBC unitsRare reportsBlood cellsCase 2Immunohematologic testingSignificant hemolysisRhD typingCase 3AlloantibodiesAutoanti
2022
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, Sheets J, Weiner DM, Geethakumari P, Kandarpa M, Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover N, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Advances 2022, 7: 88-91. PMID: 36269847, PMCID: PMC9827027, DOI: 10.1182/bloodadvances.2022008634.Peer-Reviewed Original ResearchCitationsPredictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMarginal zone lymphomaRefractory marginal zone lymphomaMulticenter cohort studyPrimary refractory diseaseOverall response rateStable diseaseCohort studyComplex cytogeneticsRefractory diseaseFirst-line therapyHigh-risk subsetType of therapyProgression of diseaseInferior OSInferior PFSMedian PFSPartial responsePredictive factorsExperimental therapiesStudy populationEligibility criteriaClinical practicePatientsResponse rateIbrutinib
2017
Therapeutic Options for Aggressive T-Cell Lymphomas.
Lue JK, Kress A, Amengual JE. Therapeutic Options for Aggressive T-Cell Lymphomas. Current Hematologic Malignancy Reports 2017, 12: 269-281. PMID: 28573497, DOI: 10.1007/s11899-017-0389-7.Peer-Reviewed Original Research
Clinical Care
Overview
Clinical Specialties
Hematology; Hematologic Oncology
Fact Sheets
Non-Hodgkin's Lymphoma
Learn More on Yale MedicineDeep Vein Thrombosis
Learn More on Yale MedicineBlood Clots in Veins, Heart and Lungs
Learn More on Yale MedicineDiffuse Large B-Cell Lymphoma
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2019
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Get In Touch
Contacts
Email
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.